Navigation Links
New Study Shows Physicians Use Numerous Sources to Inform Prescribing Decisions for Patients
Date:7/10/2008

WASHINGTON, July 10 /PRNewswire-USNewswire/ -- Over 90 percent of physicians rely on multiple sources of information when making prescribing decisions for their patients, according to a new survey released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The survey of 501 office- and hospital-based physicians, conducted by KRC Research, finds that the vast majority of doctors place the greatest emphasis on their own clinical knowledge and experience, and the unique circumstances of each individual patient, when deciding what medicines to prescribe. Physicians also identify peer-reviewed journals, clinical practice guidelines and discussions with colleagues and peers as greatly influencing their decisions.

The vast majority of physicians report that they appreciate information from pharmaceutical company representatives on drug interactions, the latest drugs and treatments, and patient assistance programs, but only 11 percent say this information greatly impacts their final prescribing decision, according to the survey. In fact, echoing the findings of earlier research from multiple studies, physicians cite patients' coverage options and drug formularies as having more of an impact on such decisions.

"America's doctors rightfully use a variety of sources to make appropriate prescribing decisions for their patients," said PhRMA President and CEO Billy Tauzin. "While physicians certainly value the information provided by America's pharmaceutical research companies in their decision-making process, it is by no means the number one factor. Rather, a physician's own clinical knowledge and their patient's distinctive situation play an appropriately greater role."

Reflecting the various factors that affect doctors' decisions, 43 percent of physicians report they prescribe about equally between brand medicines and generics, 41 percent "usually prescribe generics," and 8 percent usually prescribe a brand. Simila
'/>"/>

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Men and Women with History of Concussion Mend Differently, Study Finds
2. Men and women with history of concussion mend differently, study finds
3. Study Confirms Americans Place Their Vision at Risk Year Round
4. Global Access Project (GAP) Study Examining Patients Access to Cancer Care Featured in the Journal of the American Medical Association (JAMA)
5. HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study
6. Study finds that significant proportion of men told wifes cancer was incurable late or not at all
7. UIC in NIH-funded islet transplantation study for type 1 diabetes
8. Study points to cocktail therapy for Alzheimers
9. Study Measures Real-World Comparative Effectiveness of Asthma Controller Medications
10. AestheticEnhance.org Launches CME-Certified Case Study on Mid-Face Volumizing
11. Kaiser Permanente Study Finds Keeping a Food Diary Doubles Diet Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 62405 1New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 62405 2New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 62405 3New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology 62405 4Outpatient disc treatment gives long term back pain relief 62403 1Outpatient disc treatment gives long term back pain relief 62403 2State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 62400 1State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 62400 2State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 62400 3